CA2077670A1 - Method for enhancing antibody transport through capillary barriers - Google Patents

Method for enhancing antibody transport through capillary barriers

Info

Publication number
CA2077670A1
CA2077670A1 CA002077670A CA2077670A CA2077670A1 CA 2077670 A1 CA2077670 A1 CA 2077670A1 CA 002077670 A CA002077670 A CA 002077670A CA 2077670 A CA2077670 A CA 2077670A CA 2077670 A1 CA2077670 A1 CA 2077670A1
Authority
CA
Canada
Prior art keywords
antibody
enhancing antibody
capillary barriers
antibody transport
transport
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002077670A
Other languages
French (fr)
Other versions
CA2077670C (en
Inventor
William M. Pardridge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
William M. Pardridge
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William M. Pardridge, The Regents Of The University Of California filed Critical William M. Pardridge
Publication of CA2077670A1 publication Critical patent/CA2077670A1/en
Application granted granted Critical
Publication of CA2077670C publication Critical patent/CA2077670C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM

Abstract

A method for increasing the transcytosis of an antibody across the microvascular barrier and into the interstitial fluid of organs is disclosed. The method consists of cationizing the antibody with a cationizing agent to increase the isoelectric point of the antibody by between about 1 to about 7 to produce a cationized antibody having an isoelectric point which is less than about 11.5. The increased rate of transport across the microvascular barrier of organs makes such canonized antibodies useful for both therapeutic and diagnostic purposes.
CA002077670A 1990-03-06 1991-03-06 Method for enhancing antibody transport through capillary barriers Expired - Lifetime CA2077670C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/488,993 US5130129A (en) 1990-03-06 1990-03-06 Method for enhancing antibody transport through capillary barriers
US488,993 1990-03-06
PCT/US1991/001533 WO1991013631A1 (en) 1990-03-06 1991-03-06 Method for enhancing antibody transport through capillary barriers

Publications (2)

Publication Number Publication Date
CA2077670A1 true CA2077670A1 (en) 1991-09-07
CA2077670C CA2077670C (en) 2002-10-01

Family

ID=23941969

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002077670A Expired - Lifetime CA2077670C (en) 1990-03-06 1991-03-06 Method for enhancing antibody transport through capillary barriers

Country Status (5)

Country Link
US (1) US5130129A (en)
EP (1) EP0518982A4 (en)
JP (1) JP3210662B2 (en)
CA (1) CA2077670C (en)
WO (1) WO1991013631A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
ATE158415T1 (en) 1991-04-30 1997-10-15 Eukarion Inc CATIONIZED ANTIBODIES AGAINST INTRACELLULAR PROTEINS
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5773292A (en) * 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
AU720857B2 (en) * 1995-12-13 2000-06-15 President And Fellows Of Harvard College Use of toxin peptides and/or affinity handles for delivery compounds into cells
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2008100560A2 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators, associated pharmaceutical compositions and methods of use
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US8549912B2 (en) 2007-12-18 2013-10-08 Teradyne, Inc. Disk drive transport, clamping and testing
US7996174B2 (en) 2007-12-18 2011-08-09 Teradyne, Inc. Disk drive testing
LT2708559T (en) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US8102173B2 (en) 2008-04-17 2012-01-24 Teradyne, Inc. Thermal control system for test slot of test rack for disk drive testing system with thermoelectric device and a cooling conduit
US8238099B2 (en) 2008-04-17 2012-08-07 Teradyne, Inc. Enclosed operating area for disk drive testing systems
US8095234B2 (en) 2008-04-17 2012-01-10 Teradyne, Inc. Transferring disk drives within disk drive testing systems
US7848106B2 (en) 2008-04-17 2010-12-07 Teradyne, Inc. Temperature control within disk drive testing systems
US7945424B2 (en) 2008-04-17 2011-05-17 Teradyne, Inc. Disk drive emulator and method of use thereof
US8041449B2 (en) 2008-04-17 2011-10-18 Teradyne, Inc. Bulk feeding disk drives to disk drive testing systems
US8160739B2 (en) 2008-04-17 2012-04-17 Teradyne, Inc. Transferring storage devices within storage device testing systems
US8305751B2 (en) 2008-04-17 2012-11-06 Teradyne, Inc. Vibration isolation within disk drive testing systems
US20090262455A1 (en) 2008-04-17 2009-10-22 Teradyne, Inc. Temperature Control Within Disk Drive Testing Systems
US8117480B2 (en) 2008-04-17 2012-02-14 Teradyne, Inc. Dependent temperature control within disk drive testing systems
US8086343B2 (en) 2008-06-03 2011-12-27 Teradyne, Inc. Processing storage devices
US7920380B2 (en) 2009-07-15 2011-04-05 Teradyne, Inc. Test slot cooling system for a storage device testing system
US8466699B2 (en) 2009-07-15 2013-06-18 Teradyne, Inc. Heating storage devices in a testing system
US7995349B2 (en) 2009-07-15 2011-08-09 Teradyne, Inc. Storage device temperature sensing
US8628239B2 (en) 2009-07-15 2014-01-14 Teradyne, Inc. Storage device temperature sensing
US8687356B2 (en) 2010-02-02 2014-04-01 Teradyne, Inc. Storage device testing system cooling
US8547123B2 (en) 2009-07-15 2013-10-01 Teradyne, Inc. Storage device testing system with a conductive heating assembly
US8116079B2 (en) 2009-07-15 2012-02-14 Teradyne, Inc. Storage device testing system cooling
TWI812066B (en) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 Antibody having calcium-dependent antigen-binding ability
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
WO2014030750A1 (en) 2012-08-24 2014-02-27 中外製薬株式会社 MOUSE FcγRII-SPECIFIC Fc ANTIBODY
TW202237660A (en) 2012-08-24 2022-10-01 日商中外製藥股份有限公司 Fcγriib-specific fc region variant
WO2014145159A2 (en) * 2013-03-15 2014-09-18 Permeon Biologics, Inc. Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
KR102650420B1 (en) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN116271014A (en) 2016-08-05 2023-06-23 中外制药株式会社 Compositions for preventing or treating IL-8 related diseases
US11226390B2 (en) 2017-08-28 2022-01-18 Teradyne, Inc. Calibration process for an automated test system
US10948534B2 (en) 2017-08-28 2021-03-16 Teradyne, Inc. Automated test system employing robotics
US10983145B2 (en) 2018-04-24 2021-04-20 Teradyne, Inc. System for testing devices inside of carriers
US10775408B2 (en) 2018-08-20 2020-09-15 Teradyne, Inc. System for testing devices inside of carriers

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118379A (en) * 1974-09-06 1978-10-03 Behringwerke Aktiengesellschaft Amidated immune globulins and process for preparing them
US4219335A (en) * 1978-09-18 1980-08-26 E. I. Du Pont De Nemours And Company Immunochemical testing using tagged reagents
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
US4756907A (en) * 1978-10-17 1988-07-12 Stolle Research & Development Corp. Active/passive immunization of the internal female reproductive organs
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
US4311688A (en) * 1979-10-29 1982-01-19 Serono Laboratories Inc. Composition and method for cancer detection in humans
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4417967A (en) * 1981-11-24 1983-11-29 Georgetown University Grooved gel
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4649784A (en) * 1985-01-31 1987-03-17 Robert G. Fulks Method and apparatus for sensing activity for a keyboard and the like
US4758421A (en) * 1985-03-15 1988-07-19 The Board Of Trustees Of The Leland Stanford Junior University Bleomycin conjugates and method
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4732974A (en) * 1986-03-05 1988-03-22 Mallinckrodt, Inc. Metal ion labeling of carrier molecules
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5004697A (en) * 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification

Also Published As

Publication number Publication date
JPH05505606A (en) 1993-08-19
US5130129A (en) 1992-07-14
JP3210662B2 (en) 2001-09-17
EP0518982A4 (en) 1993-06-09
EP0518982A1 (en) 1992-12-23
WO1991013631A1 (en) 1991-09-19
CA2077670C (en) 2002-10-01

Similar Documents

Publication Publication Date Title
CA2077670A1 (en) Method for enhancing antibody transport through capillary barriers
ATE123227T1 (en) CATIONIZED ANTIBODIES FOR TRANSMISSION THROUGH THE BLOOD-BRAIN BARRIER.
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
IL132380A0 (en) Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods
CA2137561A1 (en) Photoactivation of proteins for conjugation purposes
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
ATE244888T1 (en) HUMAN CARCINOMA ANTIGEN (HCA), HCA ANTIBODIES, HCA IMMUNOASSAYS, RECORDING METHODS AND THERAPY
RU93054941A (en) COMPOSITIONS CONTAINING NANOPARTICLES ON THE SURFACE OF WHICH TILOXAPOL IS ADSORBED, METHOD FOR PRODUCING NANOPARTICLES, DIAGNOSTIC METHOD, APPLICATION OF NANOPARTICLES
FI101937B1 (en) A method for producing a monoclonal antibody that reacts with human cachectin
CA2249320A1 (en) Glycosylated humanized b-cell specific antibodies
ES8606655A1 (en) Antibodies having dual specificities, their preparation and uses therefor.
AU6264686A (en) Antibody complexes of hapten-modified diagnostic or therapeutic agents
CA2015060A1 (en) Novel antibody delivery system for biological response modifiers
DE68927438D1 (en) METHOD FOR PRODUCING MONOCLONAL ANTIBODIES WITH THE AID OF A Bacteria-free Animal
EP0378924A3 (en) Detection of neurological disease or dysfunction
FR2691167B1 (en) Method for providing metallic intermediate layers and application of the method.
CA2316411A1 (en) Humanized monoclonal antibodies that protect against shiga toxin induced disease
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
EP0845540A4 (en) Monoclonal antibody and antigen relating to human pulmonary adenocarcinoma and immunoassay method with the use of the same
EP0215131A4 (en) E87Ag ANTIGEN OF PSEUDOMONAS AERUGINOSA, MONOCLONAL ANTIBODY AGAINST IT, AND HYBRIDOMA.
AU5809290A (en) Monoclonal antibodies involved in alzheimer's disease, hybridomas secreting these monoclonal antibodies, antigen recognized by these antibodies, and their application
ES2000615A6 (en) Monoclonal antibodies against tumour-associated glycoproteins, process for their preparation and their use.
EP0338395A3 (en) Monoclonal antibodies to pseudomonas aeruginosa, their production and use
IT1233005B (en) MONOCLONAL HUMAN ANTIBODY, THERAPEUTIC COMPOSITION THAT CONTAINS IT MOBILE LINE ABLE TO PRODUCE THE ANTIBODY, PROCEDURE FOR ITS PRODUCTION
AU7144787A (en) Tumor-associated antigen (mol wt 68,000-48000; 40,000-80000; 28000-32000; 16000-19000)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121202